Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
Jain MM, Gupte SU, Patil SG, Pathak AB, Deshmukh CD, Bhatt N, Haritha C, Govind Babu K, Bondarde SA, Digumarti R, Bajpai J, Kumar R, Bakshi AV, Bhattacharya GS, Patil P, Subramanian S, Vaid AK, Desai CJ, Khopade A, Chimote G, Bapsy PP, Bhowmik S. Jain MM, et al. Among authors: patil sg, patil p. Breast Cancer Res Treat. 2016 Feb;156(1):125-34. doi: 10.1007/s10549-016-3736-9. Epub 2016 Mar 3. Breast Cancer Res Treat. 2016. PMID: 26941199 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Digumarti R, Wang Y, Raman G, Doval DC, Advani SH, Julka PK, Parikh PM, Patil S, Nag S, Madhavan J, Bapna A, Ranade AA, Varadhachary A, Malik R. Digumarti R, et al. J Thorac Oncol. 2011 Jun;6(6):1098-103. doi: 10.1097/JTO.0b013e3182156250. J Thorac Oncol. 2011. PMID: 21532506 Free article. Clinical Trial.
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, Wang Y, Varadhachary A, Zhu J, Malik R. Parikh PM, et al. J Clin Oncol. 2011 Nov 1;29(31):4129-36. doi: 10.1200/JCO.2010.34.4127. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969509 Clinical Trial.
A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.
Ranade AA, Bapsy PP, Nag S, Raghunadharao D, Raina V, Advani SH, Patil S, Maru A, Gangadharan VP, Goswami C, Sekhon JS, Sambasivaiah K, Parikh P, Bakshi A, Mohapatra R. Ranade AA, et al. Asia Pac J Clin Oncol. 2013 Jun;9(2):176-81. doi: 10.1111/ajco.12035. Epub 2012 Nov 26. Asia Pac J Clin Oncol. 2013. PMID: 23176568 Clinical Trial.
Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India.
Nimmagadda RB, Digumarti R, Nair R, Bhurani D, Raina V, Aggarwal S, Patil S, Gogoi PK, Sundaram S, Goswami C, Apte S, Chakravarthy S, Pathak A. Nimmagadda RB, et al. Indian J Med Paediatr Oncol. 2013 Oct;34(4):299-304. doi: 10.4103/0971-5851.125250. Indian J Med Paediatr Oncol. 2013. PMID: 24604961 Free PMC article.
The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from India.
Abraham G, Noronha V, Rajappa S, Agarwal A, Batra U, Somani N, Raja T, Patil S, Kaushal AM, Joshi A, Radhakrishnan V, Singh N, Babu G, Tewani R, Baghmar S, Dodagoudar C, Ananthakrishnan R, Haragadde Poppareddy S, Sharma V, Menon N, M Patil V, Joshi A, Gupta S, Prabhash K, Bajpai J. Abraham G, et al. Int J Cancer. 2022 Mar 15;150(6):1045-1052. doi: 10.1002/ijc.33868. Epub 2021 Nov 25. Int J Cancer. 2022. PMID: 34751432 Free article.
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India.
Parikh PM, Bhattacharyya GS, Biswas G, Krishnamurty A, Doval D, Heroor A, Sharma S, Deshpande R, Chaturvedi H, Somashekhar SP, Babu G, Reddy GK, Sarkar D, Desai C, Malhotra H, Rohagi N, Bapna A, Alurkar SS, Krishna P, Deo SVS, Shrivastava A, Chitalkar P, Majumdar SK, Vijay D, Thoke A, Udupa KS, Bajpai J, Rath GK, Dattatreya PS, Bondarde S, Patil S. Parikh PM, et al. South Asian J Cancer. 2021 Dec 31;10(4):213-219. doi: 10.1055/s-0041-1742080. eCollection 2021 Dec. South Asian J Cancer. 2021. PMID: 34984198 Free PMC article.
High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers.
Desai K, Nair MG, Prabhu JS, Vinod A, Korlimarla A, Rajarajan S, Aiyappa R, Kaluve RS, Alexander A, Hari PS, Mukherjee G, Kumar RV, Manjunath S, Correa M, Srinath BS, Patil S, Prasad MS, Gopinath KS, Rao RN, Violette SM, Weinreb PH, Sridhar TS. Desai K, et al. Cancer Med. 2016 Aug;5(8):2000-11. doi: 10.1002/cam4.756. Epub 2016 May 17. Cancer Med. 2016. PMID: 27184932 Free PMC article.
88 results